

RESEARCH MONOGRAPH . COMPOUND PROFILE

DMAE

A naturally occurring dimethylated ethanolamine historically developed as the prescription drug Deaner for pediatric behavioral disorders, subsequently investigated for tardive dyskinesia, senile dementia, and dermatological aging, and now positioned as a dietary supplement cholinergic agent distinguished from conventional choline sources by competitive blood-brain barrier transport affinity and membrane phospholipid incorporation.

DOCUMENT	KDC-MN-1447
ISSUED	2026-05-11
REVISION	1.0
AUTHOR	Kodiac biolabs Research
COMPOUND CLASS	Tertiary aminoalcohol choline analog and putative acetylcholine precursor with antioxidant and membrane-active properties

ABSTRACT

Dimethylaminoethanol (DMAE), also known as deanol or 2-(dimethylamino)ethanol, is a tertiary aminoalcohol endogenous to human brain tissue and present at nutritionally relevant concentrations in certain marine fish species (sardines, anchovies, salmon). Structurally, DMAE differs from choline (2-hydroxyethyltrimethylammonium) by the absence of one N-methyl group, a distinction that confers higher lipophilicity, competitive affinity for the choline carrier at the blood-brain barrier (inhibition constant approximately 159 micromolar versus Michaelis constant approximately 442 micromolar for choline), and the capacity for incorporation into membrane phospholipids as phosphatidyltrimethylaminoethanol (PDMAE) in place of phosphatidylcholine. The compound was developed by Riker Laboratories as deanol p-acetamidobenzoate (Deaner) and marketed from the 1960s through 1983 as a prescription medication for hyperkinetic syndrome (now termed attention-deficit/hyperactivity disorder) in children, on the basis of placebo-controlled trials demonstrating behavioral improvement comparable to methylphenidate at oral doses of 300 to 500 mg per day. The drug was voluntarily withdrawn in 1983 when the manufacturer elected not to submit the contemporary efficacy data required by evolving FDA regulatory standards, rather than for safety concerns. Subsequent clinical investigation extended to tardive dyskinesia, senile dementia, and dermatological applications. In tardive dyskinesia, a Cochrane systematic review and meta-analysis of randomized controlled trials concluded that DMAE was no more effective than placebo and was associated with an increased risk of adverse outcomes [1]. In senile dementia,

open-label and small controlled trials produced modest behavioral improvements without measurable cognitive or memory enhancement [2]. The dermatological evidence base is more favorable: a randomized, double-blind, placebo-controlled trial of 3 percent DMAE facial gel applied daily for 16 weeks demonstrated statistically significant improvements in forehead lines, periorbital fine wrinkles, lip shape, and overall facial skin appearance, with effects maintained on cessation and safety confirmed through 12 months of open-label extension [3]. The pharmacological mechanism remains incompletely resolved. The classical hypothesis that DMAE serves as a direct acetylcholine precursor through sequential methylation to choline and subsequent acetylation by choline acetyltransferase has been challenged by disposition studies demonstrating that DMAE is not metabolized to choline in vivo and that its principal urinary metabolite is DMAE N-oxide [4]. Alternative mechanistic proposals include competitive inhibition of choline reuptake at the blood-brain barrier (thereby elevating peripheral choline concentrations), direct incorporation into neuronal membrane phospholipids as PDMAE with consequent alteration of membrane fluidity and receptor function, free radical scavenging activity against hydroxyl and lipid radicals confirmed by electron paramagnetic resonance spectroscopy [5], and anti-inflammatory activity through suppression of interleukin-2 and interleukin-6 secretion. DMAE is also the active moiety released by hydrolysis of centrophenoxine (meclofenoxate), a nootropic drug marketed in several jurisdictions for age-related cognitive decline, in which the para-chlorophenoxyacetic acid ester linkage enhances oral bioavailability and central nervous system penetration. The compound is currently available worldwide as a dietary supplement, typically formulated as the bitartrate salt at doses of

100 to 400 mg per day. The National Toxicology Program conducted prenatal developmental toxicity studies of DMAE bitartrate in Sprague Dawley rats (2020) and reported no maternal or fetal toxicity at gavage doses up to 1000 mg/kg/day, although in vitro exposure of neurulating mouse embryos to DMAE produced dose-dependent neural tube defects and craniofacial malformations at concentrations of 250 to 750 micromolar [6]. This monograph reviews the chemistry, structural relationships, and synthesis of DMAE; the contested cholinergic pharmacology in molecular and membrane-level detail; the comprehensive disposition and pharmacokinetic record; the preclinical evidence base spanning free radical scavenging, anti-inflammatory activity, and lipofuscin reduction; the clinical evidence across behavioral, neurological, cognitive, and dermatological indications; sourcing and quality verification considerations for research-grade material; reconstitution and handling protocols; stack interactions with choline donors, acetylcholinesterase inhibitors, and anticholinergic agents; adverse events and safety signals including the NTP developmental toxicity findings; and a structured comparative assessment of five cholinergic and nootropic alternatives against DMAE on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Deanol (for the free base in pharmaceutical contexts).

Common names: DMAE, dimethylaminoethanol, dimethylethanolamine, DMEA, deanol.

Marketed names (historical and current): Deaner (Riker Laboratories; deanol p-acetamidobenzoate, United States, withdrawn 1983), Lucidril (centrophoxine; the DMAE-para-chlorophenoxyacetate ester, marketed in Europe and Asia), Nooclerin (deanol aceglumate; Russia and former Soviet states).

Chemical Abstracts Service registry numbers: 108-01-0 (free base), 5988-51-2 (bitartrate salt). The bitartrate is the principal supplement and research salt form; the free base is a hygroscopic liquid handled primarily in industrial and synthetic contexts.

International Union of Pure and Applied Chemistry name: 2-(dimethylamino)ethanol. The compound is the N,N-dimethyl derivative of 2-aminoethanol (ethanolamine), bearing two methyl groups on the nitrogen rather than the three methyl groups and quaternary ammonium of choline.

1.2 Structural class and chemistry

DMAE is a tertiary aminoalcohol and the immediate structural predecessor of choline in the methylation pathway. Where choline (2-hydroxyethyltrimethylammonium) carries a quaternary nitrogen with three methyl groups and a permanent positive charge, DMAE carries a tertiary nitrogen with two methyl groups and is uncharged at physiological pH above its pKa. This structural difference is the molecular basis for the higher lipophilicity, the ability to cross biological membranes by passive diffusion, and the competitive affinity for the choline carrier at the blood-brain barrier that distinguish DMAE from choline pharmacologically [7, 8].

Molecular formula: C₄H₁₁NO (free base); C₈H₁₇NO₇ (bitartrate salt).

Molecular weight: 89.14 g/mol (free base); 239.23 g/mol (bitartrate salt).

Physical properties (free base): Colorless to pale yellow hygroscopic liquid with a characteristic amine (fishy, ammoniacal) odor. Boiling point 134 to 135 degrees Celsius. Density 0.887 g/mL at 20 degrees Celsius. Flash point 40 degrees Celsius (closed cup). Vapor pressure 6.1 mmHg at 20 degrees Celsius. Completely miscible with water and with most organic solvents. The pKa of the dimethylamino group is approximately 9.2, placing the compound predominantly in the protonated (cationic) form at physiological pH 7.4.

Physical properties (bitartrate salt): White crystalline powder. Freely soluble in water. The bitartrate salt is the preferred form for oral supplementation and research formulation owing to its crystalline stability, defined stoichiometry, and neutral taste relative to the free base.

Stereochemistry: DMAE contains no stereocenters and is achiral. The bitartrate counterion is L-(+)-tartaric acid (the naturally occurring enantiomer); the (2R,3R) configuration of the tartrate is specified in USP and NTP reports [6].

1.3 Synthesis

DMAE is manufactured industrially by the reaction of ethylene oxide with dimethylamine under controlled temperature and pressure conditions. The reaction is exothermic and proceeds by nucleophilic ring-opening of ethylene oxide by the dimethylamine nitrogen, yielding DMAE as the primary product with small amounts of bis(2-hydroxyethyl)dimethylammonium and higher oligomers as byproducts. Industrial purification is by fractional distillation. Annual United States production volume was estimated at 100 to 250 million pounds in 2015, the large majority directed to industrial applications (epoxy resin curing catalyst, corrosion inhibitor, polyurethane foam manufacture, water-based paint production, wastewater treatment flocculant) rather than to pharmaceutical or supplement use [6].

The bitartrate salt is prepared by stoichiometric addition of L-tartaric acid to DMAE in aqueous or alcoholic solution, followed by crystallization and drying. Supplement-grade DMAE bitartrate is produced by multiple contract manufacturers at purities of 98 percent or greater by HPLC.

The p-acetamidobenzoate salt (the historical Deaner formulation) was prepared by reaction of DMAE with p-acetamidobenzoic acid in equimolar ratio, yielding a crystalline solid suitable for tableting.

Centrophenoxine (meclofenoxate) is synthesized by esterification of DMAE with para-chlorophenoxyacetic acid, typically using carbodiimide coupling or acid chloride methods, followed by salt formation (usually the hydrochloride) and recrystallization [9].

2. Abstract

Dimethylaminoethanol (DMAE, deanol) is an endogenous tertiary aminoalcohol present in human brain at trace concentrations and in marine fish at nutritionally relevant levels. The compound is the immediate N-demethylated analog of choline and has been investigated since the 1950s as a putative acetylcholine precursor, a membrane-active phospholipid modifier, a free radical scavenger, and a dermatological firming agent. Its clinical history spans four decades and multiple indications, none of which has produced a currently registered pharmaceutical product in the United States, although centrophenoxine (the DMAE-para-chlorophenoxyacetate ester) remains marketed in Europe and Asia for cognitive decline.

The pharmacological mechanism of DMAE remains incompletely resolved despite more than 60 years of investigation. The classical cholinergic precursor hypothesis holds that DMAE crosses the blood-brain barrier, undergoes enzymatic N-methylation to choline, and is subsequently acetylated by choline acetyltransferase to form acetylcholine. This hypothesis is supported by the observation that DMAE administration elevates plasma choline concentrations and that the compound exhibits higher affinity than choline for the blood-brain barrier choline carrier (K_i approximately 159 micromolar versus K_m approximately 442 micromolar) [7, 8]. However, the hypothesis has been challenged by disposition studies in rats and mice demonstrating that DMAE is not converted to choline in vivo, that it is excreted primarily as DMAE N-oxide, and that brain concentrations following oral administration are low with no accumulation [4]. Alternative or complementary mechanisms include direct incorporation into neuronal and glial membrane phospholipids as phosphatidyl dimethylaminoethanol (PDMAE), competitive inhibition of choline reuptake at the blood-brain barrier resulting in elevated peripheral choline available for brain uptake by alternative routes, direct free radical scavenging of hydroxyl and lipid radicals [5], and suppression of proinflammatory cytokine secretion (interleukin-2, interleukin-6).

The clinical evidence base is distributed across several indications. In pediatric hyperkinetic syndrome (attention-deficit/hyperactivity disorder), placebo-controlled trials from the 1960s and 1970s demonstrated behavioral improvement at oral doses of 300 to 500 mg per day, broadly comparable to methylphenidate, forming the basis for the Deaner registration [10, 11]. In tardive dyskinesia, a Cochrane

systematic review concluded that DMAE was ineffective and potentially associated with worsening of symptoms [1]. In senile dementia, small open-label trials produced behavioral but not cognitive improvement [2]. In dermatological aging, a randomized controlled trial of 3 percent DMAE facial gel demonstrated significant wrinkle reduction and skin firming sustained through 16 weeks of treatment and maintained on cessation [3]. The compound is presently available as a dietary supplement at oral doses of 100 to 400 mg daily (as the bitartrate salt), and as the active moiety of centrophenoxine.

3. Discovery and Development History

3.1 Origin and early characterization

DMAE was identified as an endogenous constituent of human brain tissue in the 1950s through chromatographic analysis of brain extracts. The structural relationship to choline (differing by one methyl group) and the emerging acetylcholine deficiency hypothesis of behavioral and cognitive disorders prompted early pharmacological investigation. Pfeiffer and colleagues at the New Jersey Neuropsychiatric Institute conducted the first systematic studies of DMAE in human subjects in the mid-1950s, reporting that oral administration produced mild central nervous system stimulation, improved concentration, and reduced fatigue without the insomnia or appetite suppression characteristic of amphetamine [12].

3.2 Pharmaceutical development as Deaner

Riker Laboratories (later acquired by 3M Pharmaceuticals) developed DMAE as the p-acetamidobenzoate salt under the trade name Deaner for the treatment of hyperkinetic syndrome in children (now classified as attention-deficit/hyperactivity disorder). The drug was approved by the FDA in the 1960s on the basis of clinical trial evidence, including a double-blind, placebo-controlled crossover study by Lewis and Young (1975) comparing deanol to methylphenidate in 74 children with learning and behavioral disorders [10]. Deanol at 500 mg per day produced behavioral improvement comparable to methylphenidate on teacher and parent rating scales. A separate placebo-controlled trial by Oettinger (1958) and confirmatory studies through the 1970s supported the indication [11, 13].

3.3 FDA withdrawal

Deaner was voluntarily withdrawn from the United States market in 1983. The withdrawal was not precipitated by safety concerns or adverse event signals. Rather, evolving FDA regulatory requirements under the Drug Efficacy Study Implementation (DESI) program mandated that drugs approved before 1962 demonstrate efficacy by contemporary standards. Riker Laboratories elected not to

invest in the new clinical trials required for continued approval, and the product was withdrawn. The compound subsequently entered the dietary supplement market, where it has remained available without interruption [14].

3.4 Tardive dyskinesia investigations

The rationale for DMAE in tardive dyskinesia arose from the dopaminergic-cholinergic imbalance hypothesis of the condition. If tardive dyskinesia reflects relative cholinergic deficit secondary to dopaminergic supersensitivity, then augmentation of central cholinergic tone through an acetylcholine precursor might restore balance. Multiple open-label reports in the late 1970s suggested benefit, prompting controlled investigation. The controlled trials produced inconsistent results, and a Cochrane systematic review by Tammenmaa-Aho et al. (2018) concluded that evidence did not support efficacy and that DMAE treatment was associated with a higher incidence of adverse outcomes than placebo [1].

3.5 Centrophenoxine and the nootropic application

Centrophenoxine (meclofenoxate, Lucidril) was synthesized in 1959 at the French National Scientific Research Center by Thuillier and colleagues as a DMAE ester designed to enhance oral bioavailability and central nervous system penetration. The para-chlorophenoxyacetic acid moiety increases lipophilicity and facilitates gastrointestinal absorption; hepatic esterases rapidly hydrolyze the ester bond to release DMAE and the inactive para-chlorophenoxyacetic acid [9]. Centrophenoxine was marketed in France and subsequently in other European, Asian, and Latin American jurisdictions for age-related cognitive decline, where it remains available as a prescription or over-the-counter medication depending on jurisdiction. The preclinical evidence for centrophenoxine includes reduction of brain lipofuscin (the intracellular accumulation of oxidized lipid-protein aggregates that increases with aging) by 28 to 42 percent in aged rats after 8 weeks of treatment [15].

3.6 Dermatological development

The skin-firming and anti-aging application of DMAE was investigated beginning in the late 1990s, driven by the observation that topical acetylcholine modulates keratinocyte and fibroblast function. Grossman (2005) reviewed the cosmetic dermatology evidence and reported favorable randomized controlled trial data for 3 per-

cent DMAE gel formulations [3]. The dermatological application is the most recently validated clinical indication and the one with the strongest contemporary evidence base.

4. Mechanism of Action

DMAE exerts biological effects through multiple proposed mechanisms, none of which is fully established as the dominant pathway. The mechanistic uncertainty reflects the compound's structural simplicity (a small molecule with a single functional group, the tertiary amine, capable of diverse interactions) and the historical difficulty of distinguishing direct cholinergic precursor effects from indirect, membrane-level, and antioxidant contributions.

4.1 Cholinergic precursor hypothesis

The classical hypothesis holds that DMAE serves as an acetylcholine precursor through a two-step pathway: (1) enzymatic N-methylation of DMAE to choline by a methyltransferase (using S-adenosylmethionine as the methyl donor), and (2) acetylation of the resulting choline by choline acetyltransferase to produce acetylcholine. This hypothesis was supported by early observations that DMAE administration elevated plasma and brain choline concentrations and that the compound produced behavioral effects consistent with enhanced cholinergic tone [12].

However, the Shipkowski et al. (2019) disposition study in rats and mice, using radiolabeled DMAE and choline with oral and intravenous administration, found no evidence of metabolic conversion of DMAE to choline [4]. The principal urinary metabolites were DMAE N-oxide and N,N-dimethylglycine. The carcinogen N,N-dimethylnitrosamine was not detected. Brain concentrations of DMAE following oral administration were low and did not accumulate with repeated dosing. These findings indicate that the direct precursor hypothesis is, at minimum, incomplete.

4.2 Blood-brain barrier choline transport competition

DMAE competes with choline for the facilitated carrier mechanism at the blood-brain barrier. Cornford et al. (1978) demonstrated by intracarotid perfusion in rats that deanol has approximately 5- to 10-fold greater affinity than choline for the blood-brain barrier choline transporter, with an inhibition constant of approximately 159 micromolar compared to the Michaelis constant for choline of approximately 442 micromolar [7]. Millington and Wurtman (1982) confirmed that deanol

acetamidobenzoate inhibits blood-brain barrier transport of choline, with the paradoxical consequence that systemic DMAE administration simultaneously raises peripheral choline concentrations (by inhibiting choline clearance from plasma) while reducing the rate of choline entry into the brain [8].

The net effect on brain acetylcholine synthesis is therefore the result of opposing forces: elevated plasma choline (which drives choline into the brain by mass action when DMAE occupancy of the carrier is incomplete) and reduced carrier-mediated choline influx. The resolution of these opposing forces likely depends on dose, duration of administration, and the degree to which alternative choline entry pathways (passive diffusion, other transporters) compensate for carrier inhibition.

4.3 Membrane phospholipid incorporation

DMAE can be incorporated into membrane phospholipids through the CDP-ethanolamine (Kennedy) pathway, producing phosphatidyl dimethylaminoethanol (PDMAE) in place of phosphatidylcholine or phosphatidylethanolamine [16]. PDMAE differs from phosphatidylcholine in headgroup charge and geometry: the tertiary amine of PDMAE is smaller than the quaternary ammonium of phosphatidylcholine and carries a different hydrogen-bonding capacity, potentially altering membrane fluidity, receptor mobility, and ion channel function.

The membrane incorporation hypothesis proposes that chronic DMAE supplementation gradually shifts the phospholipid composition of neuronal membranes toward PDMAE, producing functional consequences that include altered neurotransmitter receptor conformation and ion channel gating. This hypothesis is supported by in vitro studies demonstrating PDMAE formation in cultured cells exposed to DMAE, but the quantitative significance of PDMAE incorporation in vivo at supplement-relevant doses has not been established.

A related concern is that PDMAE incorporation may reduce the pool of phosphatidylcholine available for normal membrane function and for acetylcholine synthesis (phosphatidylcholine is a source of choline through phospholipase D-mediated hydrolysis). Chronic high-dose DMAE supplementation might therefore deplete, rather than augment, the cholinergic substrate pool, an effect that would be consistent with the inverted U-shaped dose-response relationships reported in some clinical contexts.

4.4 Free radical scavenging

Malanga et al. (2012) used electron paramagnetic resonance (EPR) spectroscopy to characterize the antioxidant properties of DMAE in vitro [5]. DMAE directly reacted with hydroxyl radicals, ascorbyl radicals, and lipid radicals in a dose-dependent manner. The free radical scavenging activity provides a molecular basis for the anti-aging and cytoprotective effects attributed to DMAE and to its ester derivative centrophenoxine, independent of any cholinergic mechanism.

4.5 Anti-inflammatory activity

In vitro studies have demonstrated that DMAE inhibits the secretion of interleukin-2 (IL-2) and interleukin-6 (IL-6) from stimulated immune cells [5, 17]. The anti-inflammatory mechanism is distinct from the cholinergic and antioxidant pathways and may contribute to the dermatological and neuroprotective effects observed in preclinical models. The molecular target for the anti-inflammatory activity (whether through membrane phospholipid modification, direct receptor interaction, or intracellular signaling modulation) has not been identified.

4.6 Composite pharmacology

The biological effects of DMAE are most plausibly the result of a composite pharmacology in which the relative contributions of cholinergic modulation, membrane phospholipid alteration, free radical scavenging, and anti-inflammatory activity vary with dose, duration, tissue, and route of administration. The absence of a single, well-characterized receptor target distinguishes DMAE from conventional pharmaceutical compounds and contributes to the difficulty of interpreting clinical trial results and establishing clear dose-response relationships.

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

DMAE free base is rapidly absorbed from the gastrointestinal tract owing to its low molecular weight, complete water miscibility, and ability to cross biological membranes by passive diffusion in the unprotonated form. The bitartrate salt dissociates in the acidic gastric environment, releasing the DMAE cation, which is absorbed predominantly in the small intestine. Time to peak plasma concentration after oral administration is approximately 1 to 2 hours in humans [14]. Oral bioavailability has not been precisely quantified in human pharmacokinetic studies but is estimated to be moderate to high based on the extensive urinary recovery of DMAE and metabolites (57 to 64 percent of dose in rat urine within 24 hours) [4].

5.2 Distribution

DMAE distributes broadly to tissues following oral or intravenous administration. In the Shipkowski et al. (2019) rat and mouse disposition study, tissue retention at 24 hours was 21 to 44 percent of the administered dose [4]. Brain concentrations were detectable but low, and no accumulation was observed with repeated dosing. The maximum brain concentration was reached approximately 0.5 to 1 hour after oral administration. Distribution to liver, heart, lungs, and kidneys was observed at lower concentrations than brain.

The blood-brain barrier transport of DMAE is carrier-mediated, sharing the facilitated choline transporter with choline and competing for the same binding site [7, 8]. The affinity of DMAE for the carrier (K_i approximately 159 micromolar) exceeds that of choline (K_m approximately 442 micromolar), meaning that DMAE is preferentially transported at equimolar concentrations. However, plasma choline concentrations in the fed state (approximately 10 to 15 micromolar) substantially exceed the plasma DMAE concentrations achieved at supplement doses, and the net in vivo transport balance depends on the relative plasma concentrations of both substrates.

Plasma protein binding of DMAE has not been formally characterized in published literature. The low molecular weight, high water solubility, and small lipophilic surface area suggest limited protein binding.

5.3 Metabolism

The Shipkowski et al. (2019) study provided the most comprehensive characterization of DMAE metabolism [4]. In rats and mice receiving oral or intravenous radio-labeled DMAE, the principal urinary metabolites were DMAE N-oxide (the major metabolite, representing approximately 13.5 percent of the excreted dose in 24-hour urine) and N,N-dimethylglycine (produced by oxidation of the hydroxyl group). Critically, choline was not detected as a metabolite, contradicting the classical hypothesis that DMAE is methylated to choline *in vivo*. The carcinogen N,N-dimethylnitrosamine was also not detected, addressing a theoretical safety concern.

The N-oxidation of DMAE is catalyzed by flavin-containing monooxygenases (FMOs) rather than by cytochrome P450 enzymes. This metabolic route is consistent with the known substrate specificity of FMO3 for tertiary amines and places DMAE metabolism outside the CYP-mediated drug interaction landscape that complicates many pharmaceutical compounds.

5.4 Elimination

Renal excretion is the principal elimination pathway. In the Shipkowski et al. (2019) study, 57 to 64 percent of the administered dose was recovered in rat urine and 16 to 43 percent in mouse urine within 24 hours [4]. Expired carbon dioxide accounted for 4 to 6 percent of the dose in rats and 13 to 22 percent in mice, indicating some oxidative metabolism to single-carbon units. The plasma elimination half-life in humans has been estimated at approximately 24 hours based on limited pharmacokinetic data, although this estimate is derived from older studies with less rigorous analytical methods and should be interpreted with caution [14].

5.5 Routes of administration

Oral: The primary route for both historical pharmaceutical (Deaner, 100 to 500 mg daily as the p-acetamidobenzoate salt) and current supplement (100 to 400 mg daily as the bitartrate salt) applications. Oral DMAE is taken with or without food; the ef-

fect of food on absorption has not been formally characterized.

Topical: 3 percent DMAE gel formulations have been studied for dermatological applications. Percutaneous absorption delivers DMAE to the dermis and epidermis; systemic absorption through topical application is minimal at the studied concentrations [3].

Intravenous: Used in preclinical pharmacokinetic studies. Not a clinical route for DMAE itself, although centrophenoquine (the DMAE ester) has been administered intravenously in some clinical research contexts.

5.6 Special populations

No formal pharmacokinetic studies in pediatric, geriatric, renally impaired, or hepatically impaired populations have been published for DMAE as a single agent. The historical pediatric dosing of Deaner (10 to 500 mg daily in children aged 6 to 12 years) was established empirically rather than through formal pediatric pharmacokinetic characterization [10, 11]. The NTP developmental toxicity studies in pregnant rats found no maternal toxicity at doses up to 1000 mg/kg/day by gavage [6]. DMAE is not recommended for use during pregnancy or lactation owing to the absence of human developmental and reproductive toxicity data and the in vitro finding of dose-dependent neural tube defects in mouse embryo culture at DMAE concentrations of 250 to 750 micromolar [6].

6. Preclinical Pharmacology

6.1 Free radical scavenging and antioxidant activity

Malanga et al. (2012) characterized DMAE as a direct scavenger of hydroxyl radicals, ascorbyl radicals, and lipid radicals using EPR spectroscopy [5]. The scavenging activity was dose-dependent and provided a molecular basis for the anti-aging effects attributed to DMAE and centrophenoxine. The hydroxyl radical scavenging is particularly relevant to oxidative stress in neuronal and dermal tissue, where hydroxyl radical generation by Fenton chemistry contributes to lipid peroxidation, protein oxidation, and DNA damage.

6.2 Lipofuscin reduction

Centrophenoxine (the DMAE ester) has been studied extensively in aged rodent models for its effect on lipofuscin, the autofluorescent lipid-protein aggregate that accumulates in postmitotic cells (neurons, cardiomyocytes, retinal pigment epithelium) with aging. Nandy and Bourne (1966) and subsequent investigators reported 28 to 42 percent reductions in brain lipofuscin content in aged rats treated with centrophenoxine for 8 weeks [15]. The mechanism of lipofuscin reduction is proposed to involve enhanced lysosomal turnover of oxidized material, facilitated by the membrane-active properties of DMAE and by its antioxidant activity reducing the rate of new lipofuscin formation. Whether DMAE alone (without the enhanced bioavailability of the centrophenoxine ester) produces comparable lipofuscin reduction in vivo has not been established.

6.3 Anti-inflammatory effects

DMAE suppresses IL-2 and IL-6 secretion from stimulated immune cells in vitro [5, 17]. The effect is concentration-dependent and has been demonstrated in peripheral blood mononuclear cell cultures and in keratinocyte models. The anti-inflammatory activity is proposed to contribute to both the dermatological skin-firming effects (through reduction of chronic low-grade dermal inflammation in photoaged skin) and to potential neuroprotective effects (through suppression of neuroinflammatory cytokine cascades).

6.4 Dermatological effects in animal models

In a D-galactose-induced skin aging model in rats, DMAE in combination with compound amino acids improved skin collagen content, antioxidant enzyme activity (superoxide dismutase, glutathione peroxidase), and histological parameters compared to the aging control group [18]. The findings support the antioxidant and membrane-stabilizing mechanisms as contributors to the dermatological anti-aging profile.

6.5 Developmental toxicity

The NTP prenatal developmental toxicity study in Sprague Dawley rats found no evidence of maternal or fetal toxicity at gavage doses of 0, 250, 500, and 1000 mg/kg/day of DMAE bitartrate administered from gestation day 6 through gestation day 20 [6]. However, in vitro studies using neurulating mouse embryo culture demonstrated significant, dose-dependent increases in the incidence and severity of neural tube defects and craniofacial hypoplasia at DMAE concentrations of 250 to 750 micromolar. The discrepancy between the in vivo (negative) and in vitro (positive) developmental toxicity findings may reflect the limited placental transfer of DMAE at the in vivo doses studied or the higher effective concentrations achievable in the direct embryo culture system.

7. Clinical Evidence Base

7.1 Attention-deficit/hyperactivity disorder (pediatric hyperkinetic syndrome)

The Deaner registration was supported by multiple clinical trials conducted between 1958 and 1975. Oettinger (1958) reported improvements in behavior and attention in hyperkinetic children treated with deanol at doses of 10 to 500 mg per day in an open-label study [13]. Lewis and Young (1975) conducted a double-blind, placebo-controlled crossover study in 74 children comparing deanol (500 mg daily) to methylphenidate (40 mg daily) and placebo over three 6-week treatment periods [10]. Deanol produced behavioral improvement on teacher and parent rating scales comparable to methylphenidate, although the improvement on core hyperactivity measures was modestly less than methylphenidate. A subsequent review by Re (1974) and by Coleman et al. (1976) confirmed the general finding that deanol produced behavioral improvement in hyperkinetic children, with effect sizes smaller than stimulant medications but clinically meaningful in some patients [11, 14].

The clinical evidence for DMAE in ADHD is historical and was generated under methodological standards substantially below those of contemporary randomized controlled trials. The studies used loose diagnostic criteria (predating the DSM-III formalization of ADHD), small sample sizes, variable dosing regimens, and short treatment durations. The evidence is sufficient to establish that DMAE produces some behavioral modification in children with hyperkinetic presentation but is insufficient by current standards to support a registration claim.

7.2 Tardive dyskinesia

The theoretical rationale for DMAE in tardive dyskinesia was the dopaminergic-cholinergic imbalance hypothesis: tardive dyskinesia was proposed to result from dopamine receptor supersensitivity with relative cholinergic insufficiency in the basal ganglia, and augmentation of central acetylcholine through DMAE might restore balance. Initial open-label reports by Casey and Denney (1974) and by Crane (1975) suggested clinical benefit [19, 20].

Controlled investigations produced inconsistent results. The Tammenmaa-Aho et al. (2018) Cochrane systematic review of cholinergic medication for antipsychotic-induced tardive dyskinesia included analysis of the DMAE evidence and concluded that DMAE was no more effective than placebo in reducing tardive dyskinesia symptoms [1]. The review further noted that DMAE treatment was associated with a statistically significant increase in adverse outcomes compared to placebo, including worsening of dyskinetic movements in some patients. The Lonowski et al. (1979) electromyographic assessment study similarly failed to demonstrate benefit [21].

The tardive dyskinesia indication is considered closed. DMAE is not recommended for this application.

7.3 Senile dementia and cognitive decline

The cholinergic hypothesis of Alzheimer's disease (that cognitive decline results from degeneration of basal forebrain cholinergic neurons and consequent acetylcholine deficiency) provided the rationale for investigating DMAE in senile dementia. Ferris et al. (1977) administered deanol openly to 14 senile outpatients for 4 weeks and reported that 10 of 14 patients improved on global behavioral ratings (p less than 0.01), but neither clinical ratings nor an extensive battery of cognitive tests revealed significant changes in memory or other cognitive functions [2]. The improvement was behavioral (alertness, engagement, participation in activities) rather than cognitive (memory, orientation, executive function).

A double-blind, placebo-controlled study in 27 patients with Alzheimer's disease produced negative results: 6 of the DMAE-treated participants dropped out due to adverse effects (drowsiness, increased confusion, elevated blood pressure), and the remaining completers showed no difference from placebo on cognitive measures [22]. Fisman et al. (1981) reviewed the clinical pharmacology of senile dementia and included DMAE among the agents that had failed to demonstrate replicable cognitive benefit [23].

The cognitive indication for DMAE as a single agent is not supported by the clinical evidence. The related compound centrophenoxine has a somewhat more developed clinical literature in age-related cognitive decline, but the evidence is predominantly from older, methodologically limited European studies.

7.4 Dermatological aging

The dermatological evidence base for DMAE is the strongest contemporary clinical dataset.

Uhoda et al. (2002) reported in a randomized clinical study that a 3 percent DMAE facial gel formulation produced significant skin-firming and wrinkle-reducing effects after a single application, with effects increasing over one week of use and reaching statistical significance compared to placebo [24]. Grossman (2005) reviewed the clinical evidence and reported the results of a randomized, double-blind, placebo-controlled trial of 3 percent DMAE facial gel applied daily for 16 weeks [3]. The treated group demonstrated statistically significant improvements in forehead lines and periorbital fine wrinkles (p less than 0.05), improvements in lip shape and fullness, and improvement in overall aging skin appearance. The skin-firming effects did not regress during a 2-week cessation period, and an open-label extension to 12 months confirmed long-term safety and sustained efficacy.

In vitro mechanistic studies demonstrated that DMAE enhanced fibroblast proliferation and that combining DMAE with mineral salts (magnesium, zinc, copper) markedly increased the fibroblast proliferative effect [3]. The proposed dermatological mechanism involves acetylcholine-mediated modulation of keratinocyte and fibroblast function (acetylcholine receptors are expressed on non-neuronal skin cells), anti-inflammatory suppression of dermal cytokine release, and antioxidant protection against UV-induced oxidative damage.

7.5 Exercise performance and mood

Limited clinical evidence exists for DMAE in exercise performance and subjective mood. Dimpfel et al. (2003) reported changes in EEG patterns consistent with increased alertness and improved emotional state in subjects receiving a DMAE-containing vitamin-mineral formulation [25]. The evidence is insufficient for clinical conclusions. DMAE is included in some commercial pre-workout and nootropic supplement formulations, but the performance and mood claims are not supported by controlled trials of adequate size and design.

8. Sourcing and Quality Verification

DMAE is widely available as a dietary supplement and as an industrial chemical. For research applications, the distinction between supplement-grade and research-grade material is important.

Supplement-grade DMAE bitartrate is manufactured by multiple contract facilities (primarily in China and India) at stated purities of 98 percent or greater. Supplement encapsulation is performed by domestic and international contract manufacturers. Supplement-grade material is subject to current Good Manufacturing Practice (cGMP) requirements under the Dietary Supplement Health and Education Act (DSHEA) of 1994 but is not subject to pharmaceutical-grade analytical requirements.

Research-grade DMAE (free base or bitartrate salt) is supplied by major chemical vendors (Sigma-Aldrich, Tokyo Chemical Industry, Alfa Aesar, Thermo Fisher Scientific) at stated purities of 99 percent or greater by gas chromatography or HPLC. Research-grade material is accompanied by a certificate of analysis and is suitable for in vitro and in vivo research applications.

Centrophenoxine (meclofenoxate hydrochloride) is available from nootropic vendors and from research chemical suppliers. Quality varies; third-party analytical confirmation is recommended.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography or gas chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (90.09 for the protonated free base $[M+H]^+$)
- Karl Fischer or loss-on-drying analysis for residual water (particularly important for the hygroscopic free base)
- Heavy metals analysis (particularly for supplement-grade material sourced from industrial chemical streams)

- Residual solvent analysis if the material was recrystallized from organic solvents

Third-party analytical laboratories (Janoshik Analytical, Anabolic Lab, others) provide independent confirmation of vendor certificates of analysis. The DMAE market is high-volume and commodity-grade, and the principal quality concern is not counterfeiting but rather impurity from industrial chemical production streams (residual ethylene oxide, dimethylamine, higher oligomers) in material not specifically manufactured for supplement or pharmaceutical use.

9. Reconstitution and Handling

DMAE free base is a liquid at room temperature (boiling point 134 to 135 degrees Celsius) and is handled as a neat liquid or diluted in aqueous or organic solvents. The free base is corrosive (pH approximately 11 in concentrated aqueous solution) and should be handled with appropriate personal protective equipment (gloves, eye protection, fume hood for neat liquid). The free base is hygroscopic and should be stored under nitrogen or argon in a sealed container. Storage at room temperature is adequate; refrigeration extends shelf life but is not required for short-term use.

DMAE bitartrate is a crystalline powder freely soluble in water at room temperature. Stock solutions for in vitro research are typically prepared at 100 to 500 mM in distilled water or phosphate-buffered saline. The pH of concentrated bitartrate solutions is mildly acidic (approximately 3.5 to 4.5) and should be adjusted to physiological pH with sodium hydroxide or buffer for cell culture applications. Stock solutions should be sterile-filtered (0.22 micrometer) for cell culture use. Aqueous solutions are stable at 2 to 8 degrees Celsius for at least 30 days and at room temperature for at least 7 days. Freeze-thaw stability has not been formally characterized; aliquoting for single-use is recommended.

For topical research formulations, DMAE is incorporated at 1 to 3 percent (weight/volume) into gel or cream vehicles. The compound is compatible with common cosmetic excipients (carbomer gels, polysorbates, glycerin). Topical formulations should be stored at room temperature protected from light.

For oral supplement use, DMAE bitartrate capsules or tablets are stored at room temperature in a dry environment. The bitartrate salt is stable under normal storage conditions for at least 24 months.

10. Stack Interactions and Combinations

DMAE interacts with several drug and supplement classes through its cholinergic modulation, blood-brain barrier transport competition, and membrane-active properties. Investigators and supplement users should consider the following:

Choline donors (alpha-GPC, CDP-choline, choline bitartrate, phosphatidylcholine): Concurrent administration with exogenous choline sources produces a complex interaction. DMAE competes with choline for the blood-brain barrier transporter, potentially reducing the central delivery of co-administered choline. Simultaneously, DMAE may elevate peripheral choline concentrations by inhibiting choline clearance from plasma. The net effect on brain acetylcholine synthesis is unpredictable and likely dose-dependent. Some practitioners recommend combining DMAE with a choline donor to ensure adequate choline substrate availability for both membrane phospholipid synthesis and acetylcholine production.

Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine, huperzine A): Concurrent use with DMAE produces additive cholinergic activity. The combination may augment cognitive effects but also increases the risk of cholinergic adverse events (nausea, diarrhea, excessive salivation, bradycardia). The combination of centrophenoxine with acetylcholinesterase inhibitors has been used clinically in some European protocols for age-related cognitive decline, but systematic safety and efficacy data for the combination are limited.

Anticholinergic agents (diphenhydramine, scopolamine, tricyclic antidepressants, antipsychotics with anticholinergic properties): Anticholinergic agents oppose the cholinergic effects of DMAE. Concurrent use may reduce the efficacy of both agents. The clinical observation that DMAE was investigated for tardive dyskinesia (an adverse effect of antipsychotic medications) reflects this pharmacological relationship.

Racetams (piracetam, aniracetam, oxiracetam): The racetam class of nootropics is commonly combined with cholinergic agents in supplement stacks on the theoretical basis that racetams increase acetylcholine turnover and thereby increase

the demand for cholinergic substrate. DMAE is one of several choline sources used in this context; alpha-GPC and CDP-choline are generally preferred for this combination owing to their more direct choline delivery.

Centrophenoxine: Concurrent DMAE and centrophenoxine supplementation is pharmacologically redundant, as centrophenoxine is hydrolyzed to DMAE in vivo. The combination would increase total DMAE exposure without providing the enhanced bioavailability that the centrophenoxine ester confers.

Antihypertensive agents: DMAE has been reported to cause mild blood pressure elevation in some patients, particularly at higher doses. Concurrent use with antihypertensive medications may require blood pressure monitoring.

11. Adverse Events and Safety

11.1 Common adverse events

The principal adverse events reported in clinical trials and in post-market supplement use are:

- Headache (the most frequently reported adverse event at oral doses above 300 mg daily)
- Insomnia (particularly with evening dosing, consistent with mild central stimulation)
- Gastrointestinal discomfort (nausea, abdominal cramping, diarrhea at higher doses)
- Muscle tension (neck and jaw tension reported anecdotally at doses above 500 mg daily)
- Vivid dreams or sleep disturbance
- Body odor (fishy odor from DMAE or trimethylamine metabolites, similar to the trimethylaminuria observed with high-dose choline supplementation)

These adverse events are dose-dependent and generally mild, resolving with dose reduction or discontinuation.

11.2 Adverse events in clinical trials

The Alzheimer's disease double-blind trial reported that 6 of approximately 14 DMAE-treated patients (43 percent) dropped out due to adverse effects including drowsiness, increased confusion, and elevated blood pressure [22]. This dropout rate is substantially higher than is typical for supplement interventions and suggests that the dementia population may be particularly susceptible to DMAE adverse effects.

The Cochrane review of DMAE in tardive dyskinesia reported that DMAE was associated with a statistically significant increase in adverse outcomes compared to placebo, including paradoxical worsening of dyskinetic movements [1].

In the tardive dyskinesia literature, severe cholinergic side effects were observed in some patients, including nasal and oral secretion, dyspnea, and respiratory distress at higher doses [19].

11.3 Developmental and reproductive toxicity

The NTP prenatal developmental toxicity study in Sprague Dawley rats found no evidence of maternal or fetal toxicity at gavage doses up to 1000 mg/kg/day of DMAE bitartrate [6]. However, in vitro exposure of neurulating mouse embryos to DMAE at concentrations of 250 to 750 micromolar produced significant, dose-dependent increases in neural tube defects and craniofacial malformations. No human developmental or reproductive toxicity data exist. DMAE is not recommended during pregnancy or lactation.

11.4 Long-term safety

Long-term safety data are limited. The 12-month open-label extension of the dermatological trial (3 percent DMAE gel, topical application) reported no safety signals [3]. Long-term oral supplementation safety has not been evaluated in controlled studies. The theoretical concern that chronic DMAE supplementation might deplete phosphatidylcholine through competitive incorporation of PDMAE into membranes has not been confirmed or refuted by clinical data.

11.5 Interactions with disease states

Patients with bipolar disorder, epilepsy, or major depression should use DMAE with caution, as the compound has been reported anecdotally to exacerbate symptoms in these populations. The mechanism is unclear but may relate to altered cholinergic tone or membrane excitability.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five cholinergic and nootropic alternatives against DMAE, evaluated against five competency standards: novelty, effect size, promising potential (current development state and trajectory), side-effect profile, and overall validation. The five comparators were selected as the principal cholinergic or nootropic agents that occupy overlapping supplement or research-clinical positioning with DMAE.

12.1 Alpha-GPC (L-alpha-glycerolphosphorylcholine)

Mechanism: Direct choline donor. Alpha-GPC is a phospholipid-derived choline source that releases choline and glycerophosphate upon hydrolysis. Unlike DMAE, alpha-GPC delivers choline directly without requiring N-methylation and does not compete with choline for blood-brain barrier transport.

Clinical evidence: Alpha-GPC has been studied in multiple clinical trials for cognitive decline and Alzheimer's disease. A 180-patient multicenter trial of alpha-GPC (400 mg three times daily for 180 days) in mild to moderate Alzheimer's disease reported significant improvement on the Alzheimer's Disease Assessment Scale cognitive subscale compared to placebo [26]. Additional trials in vascular dementia and post-stroke cognitive impairment have produced positive results. The compound is marketed as a prescription medication (Glatilin, Delecit) in some European jurisdictions.

Novelty: Low. The mechanism is conventional choline delivery.

Effect size: Moderate. Clinical trials in Alzheimer's disease and vascular dementia have demonstrated statistically significant cognitive improvements with moderate effect sizes.

Promising potential: Moderate to high. The compound has an established clinical evidence base and is widely available as both a prescription medication and a dietary supplement.

Side-effect profile: Favorable. Adverse events are mild and infrequent (headache, insomnia, gastrointestinal discomfort). No serious safety signals have been reported.

Overall validation: Moderate to high. Stronger clinical evidence base than DMAE for cognitive applications.

Comparison to DMAE: Alpha-GPC is superior to DMAE as a cholinergic substrate for cognitive applications on the basis of direct choline delivery, absence of blood-brain barrier transport competition, and a stronger clinical evidence base. DMAE retains the theoretical advantage of additional mechanisms (membrane phospholipid incorporation, free radical scavenging, anti-inflammatory activity) that alpha-GPC does not possess.

12.2 CDP-choline (citicoline)

Mechanism: Dual donor of choline and cytidine (which is converted to uridine). CDP-choline supports both acetylcholine synthesis (through choline delivery) and membrane phospholipid synthesis (through both choline and uridine, which contributes to pyrimidine nucleotide pools required for phosphatidylcholine synthesis via the Kennedy pathway).

Clinical evidence: Extensive. Multiple large clinical trials in stroke recovery, traumatic brain injury, and age-related cognitive decline. The COBRIT trial (1213 patients with traumatic brain injury) was negative on the primary endpoint, but earlier and smaller trials in stroke and cognitive decline were positive [27]. CDP-choline is marketed as a prescription medication (Somazina, Ceraxon) in many jurisdictions and as a dietary supplement in the United States.

Novelty: Low to moderate. The dual choline-uridine mechanism is mechanistically distinct from simple choline donors.

Effect size: Variable. Positive in smaller stroke and cognitive decline studies; negative in the large COBRIT traumatic brain injury trial.

Promising potential: Moderate. Widely used clinically and as a supplement despite the mixed trial results.

Side-effect profile: Favorable. One of the best-tolerated cholinergic agents in clinical use.

Overall validation: Moderate. The evidence base is larger than DMAE but is complicated by the negative COBRIT result.

Comparison to DMAE: CDP-choline provides more comprehensive cholinergic and membrane support than DMAE through its dual choline-uridine delivery. The clinical evidence base is substantially larger. DMAE is less expensive and has the distinct antioxidant and anti-inflammatory profile that CDP-choline lacks.

12.3 Centrophenoxine (meclofenoxate)

Mechanism: DMAE ester prodrug. Centrophenoxine is hydrolyzed by hepatic esterases to release DMAE and para-chlorophenoxyacetic acid. The ester linkage enhances oral bioavailability and central nervous system penetration relative to DMAE alone [9].

Clinical evidence: Moderate. European clinical studies (predominantly 1970s to 1990s) in age-related cognitive decline, dementia, and age-related memory impairment reported modest cognitive improvements. Preclinical evidence for lipofuscin reduction is strong (28 to 42 percent reduction in aged rat brain after 8 weeks) [15]. The compound is marketed as Lucidril in some jurisdictions.

Novelty: Low. The compound is a prodrug of DMAE and shares its mechanisms.

Effect size: Small to moderate in clinical studies of cognitive decline.

Promising potential: Low to moderate. The compound is established in some markets but is not actively developed for new indications.

Side-effect profile: Generally well tolerated. Adverse events similar to DMAE (insomnia, gastrointestinal discomfort, headache) but with potentially enhanced central effects owing to improved bioavailability.

Overall validation: Moderate. Longer clinical history than DMAE alone, with the lipofuscin reduction evidence providing a unique preclinical rationale.

Comparison to DMAE: Centrophenoxine delivers DMAE with enhanced bioavailability and has a more developed clinical literature. The additional cost and complexity are justified if the enhanced central nervous system delivery is operationally important. For dermatological or peripheral applications, DMAE alone is sufficient.

12.4 Huperzine A

Mechanism: Reversible acetylcholinesterase inhibitor derived from the Chinese club moss *Huperzia serrata*. Huperzine A inhibits acetylcholinesterase with a K_i of approximately 10 to 50 nanomolar, increasing synaptic acetylcholine concentrations by reducing enzymatic degradation [28]. The mechanism is fundamentally different from DMAE (which modulates acetylcholine precursor availability) and is pharmacologically analogous to the prescription acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine).

Clinical evidence: A meta-analysis of randomized controlled trials of huperzine A in Alzheimer's disease (Yang et al. 2013) included 6 trials with 454 patients and reported significant improvement on the Mini-Mental State Examination and Activities of Daily Living scales [29]. The trials were predominantly Chinese and of variable methodological quality.

Novelty: Moderate. A natural-product acetylcholinesterase inhibitor with a distinct pharmacological mechanism from DMAE.

Effect size: Moderate in the meta-analysis, comparable to donepezil at low doses.

Promising potential: Moderate. The compound is widely available as a supplement but faces competition from prescription acetylcholinesterase inhibitors with stronger regulatory validation.

Side-effect profile: Cholinergic adverse events (nausea, diarrhea, dizziness) are dose-dependent and similar in character to prescription acetylcholinesterase inhibitors but generally milder at supplement doses.

Overall validation: Moderate. The meta-analysis supports cognitive benefit in Alzheimer's disease, but the evidence quality is limited.

Comparison to DMAE: Huperzine A and DMAE operate through complementary mechanisms (enzyme inhibition versus precursor modulation). The combination is pharmacologically rational and is used in some supplement formulations. Huperzine A has stronger evidence for direct cognitive benefit; DMAE has the additional antioxidant and membrane-active properties.

12.5 Phosphatidylserine

Mechanism: Membrane phospholipid. Phosphatidylserine is an anionic phospholipid concentrated in the inner leaflet of neuronal membranes. Supplemental phosphatidylserine is proposed to support membrane integrity, neurotransmitter receptor function, and cortisol regulation. The mechanism is membrane-structural rather than directly cholinergic, but the functional consequences overlap with DMAE (membrane modification, cognitive support) [30].

Clinical evidence: Multiple clinical trials in age-related cognitive decline and Alzheimer's disease. The FDA issued a qualified health claim for phosphatidylserine and cognitive dysfunction in 2003, noting that "very limited and preliminary scientific research suggests that phosphatidylserine may reduce the risk of dementia in the elderly" [30].

Novelty: Low to moderate. Membrane phospholipid supplementation is an established concept.

Effect size: Small to moderate. Effect sizes in clinical trials have been modest and not always replicable.

Promising potential: Moderate. Widely available as a supplement with an FDA qualified health claim, though the claim language reflects the limited evidence.

Side-effect profile: Excellent. Among the best-tolerated cognitive supplements, with minimal adverse events at standard doses (100 to 300 mg daily).

Overall validation: Moderate. The qualified FDA health claim provides some regulatory validation, but the evidence is acknowledged as limited.

Comparison to DMAE: Phosphatidylserine and DMAE share the membrane-modification mechanism but differ in specifics (phosphatidylserine supports native membrane composition; DMAE introduces a non-native phospholipid species, PDMAE). Phosphatidylserine has stronger clinical evidence for cognitive benefit and a superior safety profile. DMAE has the additional cholinergic precursor and antioxidant mechanisms.

12.6 Comparator summary

The five comparator compounds occupy partially overlapping positions in the cholinergic and nootropic landscape. **Alpha-GPC** is the most direct and efficient choline donor for cognitive applications, with the strongest clinical evidence base among the conventional choline sources. **CDP-choline** provides dual choline-uridine support with the most extensive clinical trial record (including one large negative trial). **Centrophenoxine** is the bioavailability-enhanced DMAE prodrug with a unique lipofuscin-reduction dataset. **Huperzine A** operates through the complementary acetylcholinesterase inhibition mechanism with moderate clinical evidence. **Phosphatidylserine** provides membrane-structural support with a favorable safety profile and a qualified FDA health claim.

DMAE occupies a unique position in this comparator landscape as the compound with the broadest mechanistic profile (cholinergic modulation, membrane phospholipid incorporation, free radical scavenging, anti-inflammatory activity, dermatological firming) but the weakest clinical evidence base for cognitive applications among the panel. The dermatological evidence (randomized controlled trial of 3 percent DMAE gel with 16-week efficacy and 12-month safety data) is the strongest contemporary clinical dataset for any DMAE application and is a genuine differentiator. The compound's principal practical advantages are low cost, wide availability, established safety at supplement doses, and the mechanistic diversity that may make it a useful component in multi-agent supplement stacks where it contributes antioxidant and membrane-active properties that pure choline donors do not provide. Its principal practical disadvantages are the uncertain and contested cholinergic mechanism, the absence of controlled clinical evidence for cognitive benefit in any population studied to date, and the theoretical concern about phosphatidylcholine depletion with chronic use.

Investigators considering DMAE for cognitive research should recognize that the cholinergic precursor mechanism is not established by contemporary disposition data and should consider alpha-GPC or CDP-choline as primary cholinergic substrates, with DMAE evaluated as an adjunctive agent contributing antioxidant and membrane-active properties. Investigators considering DMAE for dermatological research have the strongest evidence base and the most clearly defined application.

13. References

1. Tammenmaa-Aho I, Asher R, Soares-Weiser K, Bergman H. Cholinergic medication for antipsychotic-induced tardive dyskinesia. *Cochrane Database Syst Rev*. 2018;3(3):CD000207.
2. Ferris SH, Sathananthan G, Gershon S, Clark C. Senile dementia: treatment with deanol. *J Am Geriatr Soc*. 1977;25(6):241-244.
3. Grossman R. The role of dimethylaminoethanol in cosmetic dermatology. *Am J Clin Dermatol*. 2005;6(1):39-47.
4. Shipkowski KA, Sanders JM, McDonald JD, et al. Comparative disposition of dimethylaminoethanol and choline in rats and mice following oral or intravenous administration. *Toxicol Appl Pharmacol*. 2019;378:114592.
5. Malanga G, Aguiar MB, Martinez HD, Puntarulo S. New insights on dimethylaminoethanol (DMAE) features as a free radical scavenger. *Drug Metab Lett*. 2012;6(1):54-59.
6. National Toxicology Program. NTP Developmental and Reproductive Toxicity Technical Report on the Prenatal Development Studies of Dimethylaminoethanol Bitartrate (CASRN 5988-51-2) in Sprague Dawley Rats (Gavage Studies). NTP DART Report 04. Research Triangle Park (NC): National Toxicology Program; 2020.
7. Cornford EM, Braun LD, Oldendorf WH. Carrier mediated blood-brain barrier transport of choline and certain choline analogs. *J Neurochem*. 1978;30(2):299-308.
8. Millington WR, Wurtman RJ. Deanol acetamidobenzoate inhibits the blood-brain barrier transport of choline. *Ann Neurol*. 1978;4(4):302-306.
9. Marcer D, Hopkins SM. The differential effects of meclofenoxate on memory loss in the elderly. *Age Ageing*. 1977;6(2):123-131.
10. Lewis JA, Young R. Deanol and methylphenidate in minimal brain dysfunction. *Clin Pharmacol Ther*. 1975;17(5):534-540.

11. Coleman N, Dexheimer P, DiMascio A, Redman W, Finnerty R. Deanol in the treatment of hyperkinetic children. *Psychosomatics*. 1976;17(2):68-72.
12. Pfeiffer CC, Jenney EH, Gallagher W, et al. Stimulant effect of 2-dimethylaminoethanol: possible precursor of brain acetylcholine. *Science*. 1957;126(3274):610-611.
13. Oettinger L Jr. The use of Deanol (deanol) in the treatment of disorders of behavior in children. *J Pediatr*. 1958;53(6):671-675.
14. Re O. 2-Dimethylaminoethanol (deanol): a brief review of its clinical efficacy and postulated mechanism of action. *Curr Ther Res Clin Exp*. 1974;16(11):1238-1242.
15. Nandy K, Bourne GH. Effect of centrophenoxine on the lipofuscin pigments in the neurones of senile guinea pigs. *Nature*. 1966;210(5033):313-314.
16. Ceder G, Schubert J. Effects of 2-dimethylaminoethanol (deanol) on the metabolism of choline in plasma. *J Neurochem*. 1978;30(5):1293-1296.
17. Gragnani A, Giannoccaro FB, Sobral CS, Ferreira LM. Dimethylaminoethanol affects the viability of human cultured fibroblasts. *Aesthetic Plast Surg*. 2007;31(6):711-718.
18. Li Q, Li F, Xu J, et al. Effects of dimethylaminoethanol and compound amino acid on D-galactose induced skin aging model of rat. *ScientificWorldJournal*. 2014;2014:507351.
19. Casey DE, Denney D. Dimethylaminoethanol in tardive dyskinesia. *N Engl J Med*. 1974;291(15):797.
20. Crane GE. Deanol for tardive dyskinesia. *N Engl J Med*. 1975;292(17):926.
21. Lonowski DJ, Sterling FE, King HA. Electromyographic assessment of dimethylaminoethanol (deanol) in treatment of tardive dyskinesia. *Percept Mot Skills*. 1979;45(2):415-418.
22. Fisman M, Mersky H, Helmes E. Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease. *Am J Psychiatry*. 1981;138(7):970-972.
23. Fisman M. Clinical pharmacology of senile dementia. *Prog Neuropsychopharmacol*. 1981;5(5-6):453-465.

24. Uhoda I, Faska N, Robert C, Cauwenbergh G, Pierard GE. Split face study on the cutaneous tensile effect of 2-dimethylaminoethanol (deanol) gel. *Skin Res Technol.* 2002;8(3):164-167.
25. Dimpfel W, Wedekind W, Keplinger I. Efficacy of dimethylaminoethanol (DMAE) containing vitamin-mineral drug combination on EEG patterns in the presence of different emotional states. *Eur J Med Res.* 2003;8(5):183-191.
26. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the cholinergic precursor alpha-glycerylphosphorylcholine. *Clin Ther.* 2003;25(1):178-193.
27. Zafonte RD, Bagiella E, Ansel BM, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). *JAMA.* 2012;308(19):1993-2000.
28. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. *Acta Pharmacol Sin.* 2006;27(1):1-26.
29. Yang G, Wang Y, Tian J, Liu JP. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. *PLoS One.* 2013;8(9):e74916.
30. Glade MJ, Smith K. Phosphatidylserine and the human brain. *Nutrition.* 2015;31(6):781-786.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. DMAE is not approved as a drug by the United States Food and Drug Administration. The historical prescription product Deaner (deanol p-acetamidobenzoate) was voluntarily withdrawn in 1983. The compound is available as a dietary supplement under DSHEA. Investigators should obtain analytical confirmation of identity and purity on every research-grade lot.